Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-04-15FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin's original (generic) application for fluoxetine hydrochloride.
-
FDA approval · 2019-04-08FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Original Application (Lifestar Pharma LLC)
FDA approved clomipramine hydrochloride from Lifestar Pharma LLC through an Original Application (ANDA) for a generic product.
-
FDA approval · 2019-03-20FDA Approved: FLUOXETINE — Original Application (ScieGen Pharmaceuticals, Inc)
FDA approved ScieGen Pharmaceuticals' original application for fluoxetine, authorizing the marketing of a generic fluoxetine product. Fluoxe…
-
CLINICAL_TRIALS trial_result · 2019-03-13Clinical Trial Update: Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD [Phase 2]
Phase 2 clinical trial update on novel brain-targeted strategies for pediatric obsessive compulsive disorder, with results posted after comp…
-
FDA approval · 2019-02-08FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' generic fluoxetine hydrochloride under an original application (ANDA).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-01-31FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for sertraline hydrochloride from Rising Pharma Holdings, expanding the availability of a generi…
-
FDA approval · 2019-01-25FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (NorthStar Rx LLC)
FDA approved an original generic application for fluoxetine hydrochloride from NorthStar Rx LLC. Fluoxetine hydrochloride is used to treat m…
-
FDA approval · 2019-01-10FDA Approved: FLUOXETINE — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved ScieGen Pharmaceuticals' original abbreviated new drug application for fluoxetine hydrochloride (generic fluoxetine), authorizi…
-
CLINICAL_TRIALS trial_result · 2018-11-23Clinical Trial Update: Oxytocin Administration in BDD and OCD [Phase 2]
Phase 2 clinical trial investigating oxytocin administration for body dysmorphic disorder and obsessive-compulsive disorder has completed wi…
-
FDA approval · 2018-11-21FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA granted approval for the original application of a generic fluoxetine hydrochloride product.
-
FDA approval · 2018-11-21FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' original application for clomipramine hydrochloride capsules (generic clomipramine).
-
CLINICAL_TRIALS trial_result · 2018-09-26Clinical Trial Update: Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania [NA]
A completed clinical trial evaluating response inhibition training for symptom relief in obsessive-compulsive disorder and trichotillomania;…
-
FDA approval · 2018-08-22FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for clomipramine hydrochloride submitted by SpecGx LLC. The action is a supplemental approval for th…
-
CLINICAL_TRIALS trial_result · 2018-07-30Clinical Trial Update: Deep Electrical Neuromodulation in Obsessive-compulsive Disorder
This update reports on a completed clinical trial evaluating deep electrical neuromodulation for obsessive-compulsive disorder, sponsored by…
-
CLINICAL_TRIALS trial_result · 2018-06-29Clinical Trial Update: Study of the Efficacy of GGRO: a Novel Cognitive Training App [NA]
A completed clinical trial evaluating GGRO, a cognitive training app, for reducing obsessive thoughts.
-
CLINICAL_TRIALS research · 2018-06-14Clinical Trial Update: Assisting Obsessive Compulsive Disorder (OCD) Patients With Discontinuing Long-term Serotonin Reuptake Inhibitors (SRIs) [NA]
A completed clinical trial update describing methods to help OCD patients discontinue long-term SSRI treatment.
-
FDA approval · 2018-06-12FDA Approved: PAROXETINE — Original Application (Rhodes Pharmaceuticals L.P.)
FDA approved the original abbreviated new drug application for paroxetine hydrochloride hemihydrate from Rhodes Pharmaceuticals, establishin…
-
CLINICAL_TRIALS trial_result · 2018-05-30Clinical Trial Update: Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder [Phase 4]
Phase 4 trial evaluating topiramate augmentation in obsessive-compulsive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2018-05-15Clinical Trial Update: Transcranial Direct Current Stimulation Augmented Exposure and Response Prevention for Obsessive-Compulsive Disorder [NA]
Completed clinical trial evaluating transcranial direct current stimulation augmented exposure and response prevention for Obsessive-Compuls…
-
FDA approval · 2018-05-08FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
The FDA approves Accord Healthcare, Inc.'s supplemental application for sertraline hydrochloride (sertraline HCl).
-
CLINICAL_TRIALS trial_result · 2018-04-10Clinical Trial Update: Antibiotic Treatment Trial for the PANDAS/PANS Phenotype [Phase 2]
Phase 2 trial evaluating antibiotic treatment for the PANS/PANDAS phenotype has completed, with results posted on 2018-04-10. The study also…
-
CLINICAL_TRIALS research · 2018-03-29Clinical Trial Update: Deep Brain Stimulation of the Bilateral Habenula for Treatment-Refractory Obsessive-Compulsive Disorder [NA]
This entry reports an ongoing clinical trial evaluating deep brain stimulation of the bilateral habenula for treatment-refractory obsessive-…
-
CLINICAL_TRIALS trial_result · 2018-03-22Clinical Trial Update: Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD) [Phase 1, Phase 2]
A clinical trial evaluating subthalamic nucleus stimulation for obsessive-compulsive disorder completed Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2018-03-22Clinical Trial Update: Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders [Phase 4]
Phase 4 trial of sertraline for social phobia with co-occurring anxiety and mood disorders has been terminated. The study examined sertralin…
-
CLINICAL_TRIALS trial_result · 2018-03-21Clinical Trial Update: Internet-based Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD) [Phase 2]
A Phase 2 trial evaluating internet-based cognitive behavior therapy for obsessive-compulsive disorder conducted by Karolinska Institutet ha…